InvestorsHub Logo

roiresearch

01/10/21 8:04 AM

#339235 RE: Gohel Yoerselph #339234

Look up NLS. They are working with an israeli company on a pan-viral vaccine. if you read the various pr's on the new collaboration as well as GMU furthering it's research on Brilacidin, including pan-corona virus and in vivo testing, as well as other topics noted, it seems NLS would be a benefit. They collaborate with GMU, not IPIX (as per the PR). IPIX would get the benefit of this collaboration IMHO

TheDane

01/10/21 9:02 AM

#339242 RE: Gohel Yoerselph #339234

Gibbs' Rule #39: There is no such thing as a coincidence.

olden_grumpini

01/10/21 9:21 AM

#339243 RE: Gohel Yoerselph #339234

NLS is a "preclinical" CRO. They handle research up to the point where the device/drug enters clinical trials. Given that, they would NOT be contracted to handle the clinical trial for IPIX.